Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HemaXcellerate
- Development stage
- Unknown
- Lead developer
- Regen BioPharma
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HemaXcellerate (also referred to as HemaXellerate) is an autologous cell therapy being developed by Regen BioPharma for the treatment of aplastic anemia and chemotherapy-induced bone marrow suppression. The therapy consists of autologous stromal vascular fraction (SVF) cells extracted from the patient's own adipose (fat) tissue. HemaXcellerate is designed to stimulate the body's own hematopoietic stem cells, restore the bone marrow microenvironment, and promote endogenous hematopoiesis, thereby enhancing the recovery of erythrocytes, leukocytes, and platelets following bone marrow damage.
- Other names
- HemaXellerateautologous stromal vascular fraction cells
Beyond the preview
Go deeper on HemaXcellerate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HemaXcellerate.